Skip To Main Content
Malvika Verma on Muck Rack

Malvika Verma

As seen in: Nature, PNAS, The Conversation, Science Magazine, Medical Xpress, Mary Ann Liebert, Inc., Idaho Press, Maryville Forum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Malvika

Contact Malvika, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

How Synthetic Biology Can Make a Materials Difference

|
By Adam Rothman, John Paschkewitz, Amy M. Hurwitz, Malvika Verma
| Mary Ann Liebert, Inc.
Industrial BiotechnologyVol. 19, No. 2 Industry ReportsFree Access Among the advanced technologies racing to solve big problems, synthetic biology stands out. Syn-bio, as it is known—the design and engineering of biological systems to create and improve processes and products—offers new ways of producing almost everything we consume, from flavors and fabrics to foods and fuels. We can thank syn-bio for the COVID-19 mRNA vaccines and the alternative proteins movement, among other innovations.
Open in Who Shared Issue with article?

How Synthetic Biology Can Make a Materials Difference

|
By Adam Rothman, John Paschkewitz, Amy M. Hurwitz, Malvika Verma
Our analysis shows that 79 syn-bio materials companies are currently focusing on applications from apparel to chemicals to cosmetics and have attracted almost $8 billion in private investment. (See Exhibit 1.) Both the number of funding events and the amounts have increased in recent years. Funding events jumped by almost 10% per year between 2018 and 2022, from 21 to 35, a strong indicator of rising activity.
Open in Who Shared Issue with article?

Nanotechnology approaches for global infectious diseases

|
By Ameya R. Kirtane, Malvika Verma, Robert LANGER, Paramesh Karandikar
| Nature Verified
Abstract Infectious diseases are a major driver of morbidity and mortality globally. Treatment of malaria, tuberculosis and human immunodeficiency virus infection are particularly challenging, as indicated by the ongoing transmission and high mortality associated with these diseases.
Open in Who Shared Issue with article?
See all 9 articles